

1 **Effects of surgical masks on droplet and aerosol dispersion under various oxygen**

2 **delivery modalities**

3 Takahiro TAKAZONO<sup>1,2\*</sup>, Kazuko YAMAMOTO<sup>1,3†</sup>, Ryuta OKAMOTO<sup>4</sup>, Masato

4 TASHIRO<sup>2</sup>, Shimpei Morimoto<sup>5,6</sup>, Naoki HOSOGAYA<sup>5</sup>, Taiga MIYAZAKI<sup>1,2</sup>, Katsunori

5 YANAGIHARA<sup>7</sup>, Koichi IZUMIKAWA<sup>2,3</sup>, and Hiroshi MUKAE<sup>1</sup>

6 <sup>1</sup>*Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan*

7 <sup>2</sup>*Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical*

8 *Sciences, Nagasaki, Japan*

9 <sup>3</sup>*Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan*

10 <sup>4</sup>*Visual Solution Division, Shin Nippon Air Technologies, Tokyo, Japan*

11 <sup>5</sup>*Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan*

12 <sup>6</sup>*Innovation Platform & Office for Precision Medicine, Nagasaki University Graduate School*  
13 *of Biomedical Sciences, Nagasaki, Japan.*

14 <sup>7</sup>*Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical*  
15 *Sciences, Nagasaki, Japan*

16 †, co-first author

17 **\*Correspondence:**

18 Takahiro TAKAZONO, M.D., Ph.D.

19 Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical  
20 Sciences

21 1-7-1 Sakamoto, Nagasaki 852-8501, Japan

22 Phone: +81 -95-819-7273

23 Fax: +81-95-849-7285

24 [E-mail: takahiro-takazono@nagasaki-u.ac.jp](mailto:takahiro-takazono@nagasaki-u.ac.jp)

25 **Author contributions:** T.T., K. Yamamoto, R.O., N.H., and H.M performed study design.

26 T.T., K. Yamamoto, and R.O. supervised the experiments. T.T., K. Yamamoto, M.T., T.TM.

27 K. Yanagihara, K.I., and H.M interpreted the data. S.M. supervised statical analysis. T.T. and

28 K.Y. wrote the draft, and all the authors critically reviewed the manuscript and approved the

29 final version of the manuscript.

30 **All source(s) of support:** Financial support to conduct the study was provided by Fisher &

31 Paykel Healthcare Co, Ltd. The funding source was not involved in the study design; in the

32 collection, analysis, or interpretation of data; in the writing of the manuscript; or in the

33 decision to submit the manuscript for publication.

34 **Running title:** Dispersion under HFNC with surgical masks

35 **Subject Category List:** 4.13 Ventilation: Non-Invasive/Long-Term/Weaning

36 **Total word counts:** 2284

37 \*This article has an online data supplement, which is accessible from this issue's table of

38 content online at [www.atsjournals.org](http://www.atsjournals.org).

39

40 **ABSTRACT**

41 **Rationale**

42 Aerosol dispersion under various oxygen delivery modalities, including high flow nasal  
43 cannula, is a critical concern for healthcare workers who treat acute hypoxemic respiratory  
44 failure during the coronavirus disease 2019 pandemic. Effects of surgical masks on droplet  
45 and aerosol dispersion under oxygen delivery modalities are not yet clarified.

46 **Objectives**

47 To visualize and quantify dispersion particles under various oxygen delivery modalities and  
48 examine the protective effect of surgical masks on particle dispersion.

49 **Methods**

50 Three and five healthy men were enrolled for video recording and quantification of particles,  
51 respectively. Various oxygen delivery modalities including high flow nasal cannula were  
52 used in this study. Particle dispersions during rest breathing, speaking, and coughing were  
53 recorded and automatically counted in each condition and were evaluated with or without  
54 surgical masks.

55 **Measurements and Main Results**

56 Coughing led to the maximum amount and distance of particle dispersion, regardless of  
57 modalities. Droplet dispersion was not visually increased by oxygen delivery modalities  
58 compared to breathing at room air. With surgical masks over the nasal cannula or high-flow  
59 nasal cannula, droplet dispersion was barely visible. Oxygen modalities did not increase the  
60 particle dispersion counts regardless of breathing patterns. Wearing surgical masks  
61 significantly decreased particle dispersion in all modalities while speaking and coughing,  
62 regardless of particle sizes, and reduction rates were approximately 95 and 80-90 % for larger  
63 (> 5  $\mu\text{m}$ ) and smaller (> 0.5  $\mu\text{m}$ ) particles, respectively.

#### 64 **Conclusions**

65 Surgical mask over high flow nasal cannula may be safely used for acute hypoxemic  
66 respiratory failure including coronavirus disease 2019 patients.

67

68

69

70

71 **Number of words in the abstract: 250**

72 **Keywords:** Droplet, Aerosol, COVID-19, high flow nasal cannula



## 74 INTRODUCTION

75 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes  
76 coronavirus disease 2019 (COVID-19), transmits by droplets and bioaerosols from  
77 COVID-19 patients (1). Based on the initial reports on the COVID-19 pandemic, around  
78 5–30% of COVID-19 patients develop severe respiratory distress and require intensive care  
79 unit admission to receive advanced respiratory support in terms of oxygen therapy and  
80 non-invasive and invasive ventilatory support (2). High flow nasal cannula (HFNC) is a  
81 non-invasive oxygen delivery system that allows for administration of humidified air-oxygen  
82 blends as high as 60 L/min and a titratable fraction of inspired oxygen as high as 100%.  
83 Recent studies found that HFNC use in the management of respiratory failure caused by  
84 COVID-19 was associated with a reduced rate of invasive mechanical ventilation (3, 4).  
85 However, resources, including ventilators, as well as manpower of healthcare workers, during  
86 the COVID-19 pandemic are limited. Some patients with chronic hypoxemic respiratory  
87 insufficiency need palliative respiratory care, and some bedridden elderly patients do not  
88 wish to be intubated. Therefore, it is important to wisely utilize non-invasive respiratory care,  
89 including HFNC, for both patients and healthcare workers.

90 HFNC and non-invasive positive pressure ventilation (NPPV) have been categorized as  
91 aerosol-generating procedures (AGPs) (5) based on the hypothesis that the high-velocity gas  
92 flow may promote aerosolization of patients' secretions containing viable viruses, which may  
93 then be dispersed in the environment and be inhaled by healthcare workers, thereby resulting  
94 in nosocomial infection during COVID-19 respiratory care (6). Therefore, evaluation of  
95 particle dispersion under these AGP-associated respiratory supports is critical for effective  
96 and safe treatment in severe COVID-19 patients. Some simulation studies showed that HFNC  
97 increased the dispersion amount and distance of large droplets (7, 8) and aerosols (9), while  
98 other clinical environmental studies found no significant increase in dispersed microbes (10)  
99 or aerosols (11) by HFNC. These findings indicate that the effects of HFNC on the dispersion  
100 of droplets and aerosols are controversial.

101 Notably, a study using coronavirus other than SARS-CoV-2 indicates that surgical masks  
102 reduce the number of droplets, aerosols, and viruses in the exhaled breath (12); however, no  
103 studies have investigated whether surgical masks prevent generation of droplets or small  
104 particles under respiratory management. Accordingly, this study aimed to visualize and  
105 quantify the particles generated from the human respiratory tract exposed to HFNC and other

106 oxygen delivery modalities. Additionally, the effects of surgical masks on particle dispersion  
107 under oxygen delivery modalities were also investigated.

## 108 **METHODS**

### 109 **Participants**

110 Three and five healthy men (average height and weight: 173.6 ( $\pm$ 7.4) cm and 68.6  
111 ( $\pm$ 5.6) kg, respectively) were voluntarily recruited for video recording and quantitative  
112 analysis of droplets, respectively. Inclusion criteria were as follows: 1) age  $\geq$  20 years; 2) no  
113 respiratory or systemic symptoms for 14 days before the experiments; and 3) no contact  
114 history with COVID-19 patients. Written informed consent was obtained from all the  
115 participants. All the staffs worked for these experiments wore the appropriate personal  
116 protective equipment including N95 mask and eye goggles inside the room. This study  
117 protocol was approved by the Nagasaki University Graduate School of Biomedical Sciences  
118 Research Ethics Committee (Approval number: 20092503).

### 119 **Visualization of droplet dispersion**

120 In the visualization experiment, four different oxygen delivery modes, including  
121 nasal canula at 5 L/min (non-humidified, Nakamura Medical Industry Co., Ltd.), simple  
122 oxygen mask at 10 L/min (non-humidified, Nakamura Medical Industry Co., Ltd.), HFNC at

123 60 L/min (humidified, AIRVO2/Opti flow+, Fisher & Paykel Healthcare), and NPPV with an  
124 inspiratory positive airway pressure/expiratory positive airway pressure of 10/4 cm H<sub>2</sub>O at  
125 FiO<sub>2</sub> of 21% (humidified, Philips Respironics V60/Amara Gel full face mask) were used.  
126 Particle dispersion under room air, nasal cannula, and HFNC and the dispersion patterns with  
127 or without surgical masks were recorded in the sitting position. Three breathing patterns,  
128 including rest breathing, 3 sets of speaking of sound (ta-chi-tsu-te-to and pa-pi-pu-pe-po), and  
129 3 sets of coughing, were recorded in three participants. Generalized droplets from mouths  
130 were flashed continuously by Parallel Eye D (Shin Nippon Air Technologies). Scattering  
131 light from droplets was recorded by a super high-sensitive camera (Eye Scope, Shin Nippon  
132 Air Technologies) and analyzed by Image processing software (particle eye viewer, Shin  
133 Nippon Air Technologies). The recording area was 1 meter from participants' mouths. The  
134 room temperature and humidity were maintained at 22 °C and 50%, respectively.

### 135 **Quantitative evaluation of droplet dispersion**

136 For quantitative evaluation, the droplet dispersion under four conditions including  
137 room air, nasal canula at 5 L/min, and HFNC at 30 L/min or 60 L/min (humidified) and two  
138 patterns for each condition with or without surgical masks were measured. Also, the  
139 dispersion under three breathing patterns, including rest breathing for 30 seconds, 5 sets of

140 speaking of sound (ta-chi-tsu-te-to and pa-pi-pu-pe-po), and 5 sets of coughing, were  
141 measured in five participants. Particles dispersed from participants' mouths were recorded as  
142 described above and counted by the Fine Particle Visualization System (Type-S, Shin Nippon  
143 Air Technologies) with a 1/30 sec speed, which was located in two linear columns at 25-45  
144 and 60-80 cm from the mouth, respectively (Supplement Figure 1). Particles sized  $> 5 \mu\text{m}$   
145 and  $> 0.5 \mu\text{m}$  were automatically counted independently. The study was performed in an  
146 air-controlled room with a down-flow of 0.3 m/sec from the air supply system. The room  
147 temperature and humidity were maintained at 27 °C and 40%, respectively. Recorded  
148 movies were blinded to participants during both experiments, and participants had a 10 ml of  
149 water to keep the oral cavity hydrated between each experiment condition.

## 150 **Statistical Analysis**

151 Differences in continuous numbers between the two groups were analyzed by ratio  
152 paired t-test. A p-value of  $< 0.05$  was considered statistically significant. All the graphs were  
153 drawn using GraphPad Prism ver.8 (GraphPad Software).

## 154 **RESULTS**

155 **Evaluation of visualization of droplet dispersion under various oxygen delivery**  
156 **modalities**

157 Individual differences were observed in the amounts of droplets; however, three participants  
158 showed similar trends at each condition. The accumulated droplet ( $> 5 \mu\text{m}$ ) dispersion in a  
159 representative participant is shown in Figure 1, and movies are shown in Supplemental videos.  
160 In the room air, droplet particles were barely visible at rest breathing but were observed while  
161 speaking and coughing. Some droplets reached over 60 and 100 cm from mouths while  
162 speaking and coughing. While coughing, visible particles had the largest amounts, the  
163 farthest distance, and the largest size. Visible droplet dispersion was neither increased nor  
164 farther reached among oxygen delivery modalities. Notably, by wearing a surgical mask over  
165 the nasal cannula or HFNC, droplet dispersion was barely visible, even while speaking and  
166 coughing.

167 With the simple oxygen mask of 10 L/min, small amounts of visible droplets floated from  
168 the slit between the oxygen mask and face while coughing. With the NPPV mode, droplets  
169 were visible through the expiration port of full-face NPPV masks and floated beyond the  
170 distance of 50 cm. These findings were observed in two of the three participants (Figure 1  
171 and Supplement Figure 2 and 3).

172 **Quantitative evaluation of droplet dispersion under various oxygen delivery modalities**

173           The quantification results of droplet and aerosol dispersion are shown in Figure 2.

174   Droplet dispersion counts at coughing without surgical masks showed a 1-log increase

175   compared to those at speaking and more than a 2-log increase compared to those at rest

176   breathing. At rest breathing, particle counts were not different among all oxygen delivery

177   modalities with surgical mask usage. Counts of droplets ( $> 5 \mu\text{m}$ ) and smaller particles

178   including aerosols ( $> 0.5 \mu\text{m}$ ) were not different under nasal cannula or HFNC and room air

179   while speaking and coughing. Furthermore, the increased flow rate of HFNC (from 30 L/min

180   to 60 L/min) did not affect the particle counts in each pattern, even while coughing.

181           We examined the reduction ratios of wearing surgical masks in the particle count of

182   each size under each oxygen delivery modality at each breathing pattern (Table 1). As a result,

183   at speaking and coughing under the nasal cannula or the HFNC, we observed decreases in the

184   particle counts by wearing surgical masks ( $P < 0.05$ , the t-test for the null-difference within a

185   participant between the usage of the surgical mask.). At speaking and coughing, reduction

186   ratios of particle dispersion by wearing surgical masks were approximately 95% and 80-90%

187   in droplets ( $> 5 \mu\text{m}$ ) and smaller particles including aerosols ( $> 0.5 \mu\text{m}$ ), respectively (Table

188   1). Interestingly, reduction efficacy of dispersion by surgical masks tended to be higher under

189   NHFC than under nasal cannula while speaking.

190 In terms of dispersion distance of droplets and aerosols, the number of particles  
191 obtained from two separate counters is shown in Figure 3. Dispersion distance of droplets (>  
192 5  $\mu\text{m}$ ) and smaller particles including aerosols (> 0.5  $\mu\text{m}$ ) decreased at the far side compared  
193 to the near side. Smaller particles including aerosols (> 0.5  $\mu\text{m}$ ) obviously decreased at the far  
194 side compared to the near side while speaking; however, they remained at the far side while  
195 coughing. Surgical masks effectively reduced aerosol dispersion, even while coughing.  
196 Compared to nasal cannula, HFNC did not increase aerosol dispersion in the near or far side.  
197 Moreover, the flow rate of 60 L/min did not increase aerosol dispersion compared to that of  
198 30 L/min in the near or far side.

## 199 **DISCUSSION**

200 In this study, we performed two experiments in different oxygen delivery modes and  
201 modalities. Based on the particle visualization study, we found that visible droplets reached  
202 60–80 cm while speaking and 1 m while coughing in a sitting position; the findings are  
203 similar to those in a recent study (13). In addition, these findings support results in a  
204 systematic meta-analysis, which showed that a physical distance of 1 m or more is optimum  
205 to reduce person-to-person virus transmission and to keep healthcare workers from  
206 contracting the SARS-CoV-2 infection (14). Surgical masks obviously reduced visible

207 droplets in our study; these findings in photos and videos confirm the effect of surgical masks  
208 on transmission of viral particles in society and in hospitals caring for oxygen-delivered  
209 patients during the pandemic. Based on our quantification study, the majority of particles  
210 produced by the HFNC mode were smaller particles or aerosols; the finding is supported by a  
211 previous study, which measured the median diameter of particles (range, 1.19-1.42  $\mu$  m)  
212 produced by HFNC (11). Coughing increased the amount and distance of dispersing smaller  
213 particles, suggesting that aerosols from lung alveoli were especially dispersed by coughing.  
214 HFNC did not increase the number of smaller particles or aerosols compared to conventional  
215 nasal cannula or room air while coughing. These findings suggest that oxygen delivery  
216 devices investigated in this study are potential aerosol-dispersing procedures, but not AGPs  
217 (15).

218 In the NPPV mode, although only one type of NPPV mask was evaluated in this study,  
219 floated droplets were visible while coughing and might harm bioaerosol dispersion during  
220 treatment. In addition, droplets and aerosols were approximately 10-times more during  
221 coughing than during speaking, regardless of types of oxygen devices. The difference is  
222 larger than that in a previous study (11), which showed about a twice increased number of  
223 particles while coughing in any devices; however, those particles were assessed only about 5

224 cm away from mouths in that study (11). Notably, surgical masks significantly reduced  
225 dispersion counts of both droplets and aerosols while speaking or coughing, regardless of  
226 oxygen delivery modes. Indeed, surgical masks effectively reduced over 90% of droplets and  
227 over 95% of aerosols during HFNC. While speaking, the reduction rate of particle dispersion  
228 by surgical masks during HFNC was higher than that during nasal cannula. This result is  
229 supported by previous findings of velocity map of gas flow experiments (16), which showed  
230 that the proportion of droplets ( $> 5 \mu\text{m}$ ) captured by surgical masks was higher during 40  
231 L/min of HFNC than during 6 L/min of nasal cannula, suggesting that high-velocity particles  
232 are more likely to be captured into surgical masks than lower velocity particles (16). In our  
233 study, 60 L/min of HFNC did not increase counts and dispersion distance of droplets or  
234 aerosols compared to 30 L/min of HFNC; the finding is consistent with that in a previous  
235 study (11). The particle dispersion may be limited when the cannula of HFNC is properly  
236 fitted (9), even at the highest flow rate.

237         This study has several limitations. First, this study included a relatively small  
238 number of individuals. The particle experiments were performed in healthy volunteers, but  
239 not in viral pneumonia patients. Second, only one-sided visualization was recorded, and  
240 dispersion in the three-dimensional space was not evaluated. Third, the particle quantification

241 experiment was performed at a mild down flow, which might affect the natural distance of  
242 dispersion, and the design of the quantification experiment limited the detection area of  
243 particles. Forth, particles with a size of less than 0.5  $\mu\text{m}$  were not detectable in our study;  
244 however, these smaller particles are not speculated to contain enough viruses for transmission  
245 (17). To date, the virus load of SARS-CoV-2 in aerosols generated from coughing or  
246 included in exhaled breath from patients with COVID-19 has not been reported (18),  
247 although SARS-CoV-2 has been found to be viable in room air for 3 hours (19). The virus  
248 load or concentration required for transmission in humans needs to be further investigated.

249 In summary, with our study, HFNC did not increase either quantity or distance of droplet and  
250 aerosol dispersion compared to standard nasal cannula therapy, and surgical masks decreased  
251 particle dispersion and improved safety of healthcare workers during HFNC, even at the  
252 highest flow, in appropriate infection control settings. Our findings support that surgical  
253 masks should be recommended for patients with acute hypoxemic respiratory failure due to  
254 viral pneumonia, including COVID-19 patients. Further studies are warranted to examine  
255 viral spread and risks associated with HFNC therapy in COVID-19 patients.

#### 256 **Conflicts of interest**

257 None

258 **Acknowledgement**

259 We would like to thank technical staffs in Shin Nippon Air Technologies for their supports in

260 this study.

261

## 262 **References**

- 263 1. Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, Sun L, Duan Y, Cai J, Westerdahl D, Liu  
264 X, Xu K, Ho KF, Kan H, Fu Q, Lan K. Aerodynamic analysis of SARS-CoV-2 in two  
265 Wuhan hospitals. *Nature* 2020; 582:557-560.
- 266 2. Kaur R, Weiss TT, Perez A, Fink JB, Chen R, Luo F, Liang Z, Mirza S, Li J. Practical  
267 strategies to reduce nosocomial transmission to healthcare professionals providing  
268 respiratory care to patients with COVID-19. *Crit Care* 2020; 24:571.
- 269 3. Patel M, Gangemi A, Marron R, Chowdhury J, Yousef I, Zheng M, Mills N, Tragesser L,  
270 Giurintano J, Gupta R, Gordon M, Rali P, D'Alonso G, Fleece D, Zhao H, Patlakh N,  
271 Criner G. Retrospective analysis of high flow nasal therapy in COVID-19-related  
272 moderate-to-severe hypoxaemic respiratory failure. *BMJ Open Respir Res* 2020;  
273 7:e000650..
- 274 4. Demoule A, Vieillard Baron A, Darmon M, Beurton A, Geri G, Voiriot G, Dupont T,  
275 Zafrani L, Girodias L, Labbe V, Dres M, Fartoukh M, Azoulay E. High-flow nasal  
276 cannula in critically III patients with severe COVID-19. *Am J Respir Crit Care Med*  
277 2020; 202:1039-1042.

- 278 5. Judson SD, Munster VJ. Nosocomial transmission of emerging viruses via  
279 aerosol-generating medical procedures. *Viruses* 2019; 11:940.
- 280 6. Cheung JC, Ho LT, Cheng JV, Cham EYK, Lam KN. Staff safety during emergency  
281 airway management for COVID-19 in Hong Kong. *Lancet Respir Med* 2020; 8:e19.
- 282 7. Elshof J, Hebbink RHJ, Duiverman ML, Hagmeijer R. High-flow nasal cannula for  
283 COVID-19 patients: risk of bio-aerosol dispersion. *Eur Respir J* 2020; 56:2003004.
- 284 8. Loh NW, Tan Y, Taculod J, Gorospe B, Teope AS, Somani J, Tan AYH. The impact of  
285 high-flow nasal cannula (HFNC) on coughing distance: implications on its use during  
286 the novel coronavirus disease outbreak. *Can J Anaesth* 2020; 67:893-894.
- 287 9. Hui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, Gin T, Chan MTV. Exhaled air  
288 dispersion during high-flow nasal cannula therapy versus CPAP via different masks.  
289 *Eur Respir J* 2019; 53:1802339.
- 290 10. Leung CCH, Joynt GM, Gomersall CD, Wong WT, Lee A, Ling L, Chan PKS, Lui PCW,  
291 Tsoi PCY, Ling CM, Hui M. Comparison of high-flow nasal cannula versus oxygen  
292 face mask for environmental bacterial contamination in critically ill pneumonia  
293 patients: a randomized controlled crossover trial. *J Hosp Infect* 2019; 101:84-87.

- 294 11. Gaeckle NT, Lee J, Park Y, Kreykes G, Evans MD, Hogan CJ, Jr. Aerosol generation  
295 from the respiratory tract with various modes of oxygen delivery. *Am J Respir Crit*  
296 *Care Med* 2020; 202:1115-1124.
- 297 12. Leung NHL, Chu DKW, Shiu EYC, Chan KH, McDevitt JJ, Hau BJP, Yen HL, Li Y, Ip  
298 DKM, Peiris JSM, Seto WH, Leung GM, Milton DK, Cowling BJ. Respiratory virus  
299 shedding in exhaled breath and efficacy of face masks. *Nat Med* 2020; 26:676-680.
- 300 13. Wang H, Li Z, Zhang X, Zhu L, Liu Y, Wang S. The motion of respiratory droplets  
301 produced by coughing. *Phys Fluids (1994)* 2020; 32:125102.
- 302 14. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schunemann HJ, authors C-SURGEs.  
303 Physical distancing, face masks, and eye protection to prevent person-to-person  
304 transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis.  
305 *Lancet* 2020; 395:1973-1987.
- 306 15. Dhand R, Li J. Coughs and Sneezes: Their Role in Transmission of Respiratory Viral  
307 Infections, Including SARS-CoV-2. *Am J Respir Crit Care Med* 2020; 202:651-659.
- 308 16. Leonard S, Atwood CW, Jr., Walsh BK, DeBellis RJ, Dungan GC, Strasser W, Whittle  
309 JS. Preliminary findings on control of dispersion of aerosols and droplets during

310 high-velocity nasal insufflation therapy using a simple surgical mask: implications for

311 the high-flow nasal cannula. *Chest* 2020; 158:1046-1049.

312 17. Wang Y, Xu G, Huang YW. Modeling the load of SARS-CoV-2 virus in human expelled

313 particles during coughing and speaking. *PLoS One* 2020; 15:e0241539.

314 18. Fennelly KP. Particle sizes of infectious aerosols: implications for infection control.

315 *Lancet Respir Med* 2020; 8:914-924.

316 19. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN,

317 Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, de Wit E, Munster

318 VJ. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.

319 *N Engl J Med* 2020; 382: 1564-1567.

320

321

322

323 **Figure Legends**

324 **Figure 1.** Representative accumulated photographs of droplet (> 5 µm) dispersion at rest  
325 breathing, speaking, and coughing at room air and with four different oxygen delivery  
326 modalities (5L/min of nasal cannula, 60L/min of HFNC, 10L/min of oxygen mask, and  
327 NIPPV(IPAP 10cm, EPAP 4cm)), with and without surgical masks. Abbreviations; HFNC,  
328 high flow nasal cannula.

329

330 **Figure 2.** Number of droplet (>5 µm) and particles including aerosol (>0.5 µm) dispersion at  
331 room air and with three different oxygen delivery modalities (5L/min of nasal cannula,  
332 30L/min or 60L/min of HFNC), in three breathing patterns (rest breathing, speaking, and  
333 coughing), with or without surgical masks. Abbreviations; HFNC, high flow nasal cannula. \*  
334  $P < 0.05$ , analyzed by ratio paired t-test.

335

336 **Figure 3.** Numbers of droplet (>5 µm) and particles including aerosol (>0.5 µm) dispersion  
337 and their distance obtained by two separate counters (near side: 25-45 cm and far side: 60-80  
338 cm from the mouth). Those particles were counted at room air and three different oxygen  
339 delivery modalities (5L/min of nasal cannula, 30L/min or 60L/min of HFNC), in three

340 breathing patterns (rest breathing, speaking, and coughing), with or without surgical masks.

341 Abbreviations; HFNC, high flow nasal cannula.

342

343 **Table 1.** Reduction effect of wearing surgical masks on particle dispersion with various  
 344 oxygen delivery modalities.

345

Reduction ratio (Surgical mask +/- )				
		Average (min - max) %		
Particle sizes	Oxygen delivery modes	Rest breathing	Speaking	Coughing
>5 µm	Room air	21.15 (5 - 333.3)	17.81 (3.5 - 33.7)	5.15 (2 - 21.4)
	Nasal canula (5 L/min )	58.97 (19.4 -120)	7.39 (1.9 - 17.6)	4.28 (0.8 - 19.7)
	HFNC (30 L/min)	72.73 (23.1 - 180)	5.35 (1 - 10.9)	3.70 (1.3 - 18.1)
	HFNC (60 L/min)	116.67 (61.5 - 255)	3.64 (0.6 -15.3)	4.29 (2.2 - 26.3)
>0.5 µm	Room air	48.0 (24.7 - 119.2)	26.39 (8.7 - 64.6)	21.71 (14.3 - 23.8)
	Nasal canula (5L/min )	62.79 (39.9 - 121.5)	22.03 (8.8 - 38)	13.01 (5.8 - 37.1)
	HFNC (30 L/min)	50.45 (27.9 - 106.9)	11.65 (5.1 - 25.5)	10.11 (4.6 - 14.2)
	HFNC (60 L/min)	59.03 (30.4 - 157)	10.09 (1.3 - 37.4)	11.50 (8.7 - 16.3)

346

347 **ONLINE DATA SUPPLEMENT**

348 **Supplemental videos.**

349 The movie of droplet ( $> 5 \mu\text{m}$ ) dispersion in a representative participant at rest breathing,  
350 while speaking, and while coughing at room air and with four different oxygen delivery  
351 modalities, including a nasal cannula at 5 L/min, a simple oxygen mask at 10 L/min, HFNC at  
352 60 L/min, and NPPV at an inspiratory positive airway pressure/expiratory positive airway  
353 pressure of 10/4 cm H<sub>2</sub>O at FiO<sub>2</sub> of 21% with or without surgical mask. Abbreviations;  
354 HFNC, high flow nasal cannula.

355

356 **Supplemental Figure 1.**


357 Schematic diagram of methods for quantitative evaluation of droplets production. Dispersing  
358 particles sized  $> 5 \mu\text{m}$  and  $> 0.5 \mu\text{m}$  were counted by the Fine Particle Visualization System  
359 (Type-S, Shin Nippon Air Technologies), which was located in two linear columns at 25-45  
360 and 60-80 cm from the mouth, respectively.

361


362 **Supplemental Figures 2 and 3** Accumulated photographs of droplet ( $> 5 \mu\text{m}$ ) dispersion with  
363 two other participants. At rest, while breathing, while speaking, and while coughing at room

- 364 air and with three different oxygen delivery modalities, including a nasal cannula at 5 L/min,
- 365 HFNC at 30 L/min, and at 60L/min with or without surgical mask. Abbreviations; HFNC,
- 366 high flow nasal cannula.

**Figure 1.**



**Figure 1.**





**Figure 3**

